NEW YORK (GenomeWeb News) – Women's health diagnostics company Inex Innovations Exchange announced today a partnership with BGI to create a next-generation sequencing facility in Singapore to offer molecular genetic tests.

The first test to be offered will be iGeneScreen, a non-invasive test developed by BGI to detect fetal chromosomal abnormalities. Using a 5 milliliter blood sample from expectant mothers at 12 weeks or later into their pregnancies, the test analyzes fetal DNA in maternal blood for trisomies 21, 18, and 13.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.